Redcare Pharmacy stock gets CardLink support through March 2028

Published on 09/28/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock traded at EUR 61.10 on September 28, 2026, at 11:19 a.m. CEST. Q2 adjusted EBITDA margin reached 3.50 percent and H1 revenue rose 19 percent.

Flatlay mit Aktienzertifikat, ISIN-Karte, Pillenblistern und Stethoskop von oben — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt Flatlay mit Aktienzertifikat, ISIN-Karte und markenfreien Apotheken-Utensilien, Illustration mit AI erstellt.

Redcare Pharmacy stock (ISIN NL0012044747) was trading at EUR 61.10 on Xetra on September 28, 2026, at 11:19 a.m. CEST, up 0.99 percent from the prior close. The company secured continued digital prescription access in Germany after Redcare Pharmacy reported on September 15, 2026, that CardLink approval had been extended through March 31, 2028.

CardLink extends the digital runway

The extension keeps app-based e-prescription redemption available while the German healthcare system develops PoPP, or Proof of Patient Presence, as the future solution. For Redcare, the regulatory decision protects an established route for prescription customers and gives the company a longer transition period.

The announcement is operational rather than a new financial forecast. Its importance lies in continuity: Redcare's German prescription business depends on digital customer adoption, while the company prepares for the next technical standard.

Q2 growth meets a margin test

On the July 29, 2026 earnings call, Yahoo Finance reported that Redcare's Q2 revenue increased 20 percent year over year. Adjusted EBITDA margin reached 3.50 percent in Q2, while H1 revenue rose 19 percent to EUR 1.70 billion from EUR 1.40 billion.

The same call highlighted a counter-factor for investors: management expected group growth below 20 percent in July and forecast a slowdown in German prescription growth during the second half because of tougher comparisons. H1 adjusted EBITDA margin stood at 2.60 percent, and H1 EBIT was positive at EUR 9.00 million.

Analyst target stays above the market

MarketScreener reported on September 3, 2026, that Jefferies maintained a Buy rating and a EUR 97.00 price target. The target lies 58.76 percent above the Xetra price of EUR 61.10, although the target is an external analyst view rather than company guidance.

Redcare Pharmacy stock was 32.19 percent below its 52-week high of EUR 90.10 and above its 52-week low of EUR 30.20 on September 28, 2026. The session volume stood at 3,868 shares by the quoted time, while market capitalization was EUR 1.2 billion.

Next results arrive in October

MarketScreener lists October 28, 2026, as the scheduled release date for Redcare's third-quarter results. That report should show whether the regulatory continuity from CardLink is accompanied by sustained prescription growth and further margin progress.